Text Size

Human Tissue Repository for Wound Care

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
KCI USA, Inc.
ClinicalTrials.gov Identifier:
NCT01432054
First received: September 8, 2011
Last updated: September 9, 2011
Last verified: September 2011
History of Changes
  Purpose

The objective of this study is to create a Human Tissue Repository to be used as a resource for future tissue repair research at KCI USA, Inc.


Condition
Human Tissue Repository

Study Type: Observational
Official Title: Human Tissue Repository for Wound Care

Further study details as provided by KCI USA, Inc.:

Primary Outcome Measures:
  • The study design is a collection of human biological specimens in Subjects with various wound classifications and types for the purpose of a Human Tissue Repository to be used as a resource for future tissue repair research at KCI USA, Inc [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

wound biopsy


Estimated Enrollment: 750
Study Start Date: February 2009
Estimated Study Completion Date: February 2014
Detailed Description:

The study design is a multicenter study involving the collection of human biological specimens in Subjects with various wound classifications and types for the purpose of a Human Tissue Repository to be used as a resource for future tissue repair research at KCI USA, Inc. Subjects participating in this study will have a 6mm tissue punch biopsy or equivalent tissue specimen harvested from the healthiest margin of the wound. Tissue collection may occur at Visits 2, 3, 4 and 5. Visit 2 may be combined with Screening, Visit 1. Subjects will have a minimum of one (1) and a maximum of four (4) specimen collection visits. Specimens may be collected from one or multiple different tissues (connective tissue, muscle, bone, and dermis) at any or all visits. Each specimen will be placed in a separate appropriate vial. Necrotic tissue with eschar and bodily fluids such as blood, wound fluid or sputum will not be collected. Tissue from healthy, healing wounds will also be accepted. Tissue collection visits shall occur at least twenty-four (24) hours apart. Ten (10) to twenty-five (25) percent of the sites will be selected to collect all the specimens in cryovials containing a pre-aliquoted amount (1.5mL) of RNAlater. Ten (10) to twenty-five (25) percent of the sites will be selected to collect all the specimens in cryovials containing a pre-aliquoted amount of HypoThermosol. The remaining sites will collect all the specimens in a vial containing no diluents. All samples will be coded by the collection site prior to shipment to KCI.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Eligible subjects with acute or chronic wounds and whose wounds encompass one of the following wound types will be enrolled: traumatic, diabetic, pressure ulcer, burns, or dehisced wounds. Enrollment will continue up to 5 years. KCI may determine at any time that sufficient samples have been obtained and cease enrollment.

Criteria

Inclusion Criteria:

  • Subject's wound is acute or chronic and classified as one of the following wound types: diabetic, pressure ulcer, burn, traumatic or dehisced, and Subject signs the separate informed consent form for the study. The consent process for tissue collection should occur separately from any surgical consent.
  • Subject is reported to be physically and mentally able and willing to comply with the Protocol.
  • Subject is between 18 - 75 years old.

Exclusion Criteria:

  • Reported presence of Human Immunodeficiency Virus.
  • Reported presence of Acquired Immune Deficiency Syndrome.
  • Reported presence of Hepatitis.
  • Reported presence of cancer in the wound.
  • Reported presence or suspected presence of infection (indicated by signs and symptoms of infection such as redness/swelling, or a positive culture, etc.)
  • Presence of untreatable osteomyelitis.
  • Presence of any other severe concurrent disease, which, in the judgment of the investigator, would make the subject inappropriate for entry into the study.
  • Necrotic tissue with eschar present that cannot be debrided.
  • Subject is unwilling or unable to comply with the protocol.
  • Subject is a suspected or known intravenous drug user.
  • Donation of tissue which, in the judgment of the investigator, may pose venous or arterial compromise.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: KCI USA, Inc.
ClinicalTrials.gov Identifier: NCT01432054     History of Changes
Other Study ID Numbers: VACP2007-24
Study First Received: September 8, 2011
Last Updated: September 9, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by KCI USA, Inc.:
Human Tissue Repository

ClinicalTrials.gov processed this record on May 23, 2013